Drug intelligence / Profile preview

OB-24-01

Development stage: Preclinical
Lead developer: OCMS Bio
Modality: Small Molecules
Administration: Oral

Overview

OB-24-01 is a preclinical-stage oral therapeutic candidate being developed by OCMS Bio for the treatment of respiratory syncytial virus (RSV) infection. The drug is designed as an RSV fusion inhibitor, leveraging the company's proprietary Oral Controlled Molecular System (OCMS) platform to enable effective oral administration. By targeting the viral fusion process, OB-24-01 aims to prevent the virus from entering host cells and replicating. As of 2025, the program is undergoing preclinical evaluation to support future clinical development.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on OB-24-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OB-24-01.

Explore the full profile